Calliditas will present new secondary, biomarker, and mechanistic analyses from the Phase 3 NefIgArd study at the 2026 World Congress of Nephrology. Data further support Nefecon's gut–targeted, disease–modifying mechanism of action in IgA nephropathy. Calliditas to present seven posters and sponsor a scientific symposium highlighting the evolving IgAN treatment paradigm. STOCKHOLM, March 30, 2026 /PRNewswire/ -- Calliditas Therapeutics AB, an Asahi Kasei company, announced today that new data fr

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced final 20-week study completion data from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324, a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration

ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a definitive merger agreement (the “Merger Agreement”) to acquire Kezar Life Sciences, Inc. (NASDAQ: KZR), a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in

New company formed to unlock value from Phase 3-ready and next-generation therapies for cardiogenic shock and acute heart failure Targeting completion of first Phase 3 study for istaroxime to enable NMPA registration by 2027 Advancing next-generation oral heart failure program towards first-in-human studies by 2027 DURHAM, N.C. and SINGAPORE, March 30, 2026 /PRNewswire/ -- Seismic Pharma, a newly formed biopharmaceutical company, today announced its launch and initial financing led by Panacea Ca

Updates on HeadSMART II, Geriatric trials presented at clinical meetings Promising early results in Prolight Diagnostics Point-of-Care collaboration Multi-model models presented for TBI, neurodegeneration differential diagnosis RICHMOND, Va., March 30, 2026 /PRNewswire/ -- BRAINBox Solutions today provided an update on the clinical, development, and corporate progress in its BRAINBox TBI diagnostic/prognostic test program. The BRAINBox tests for concussion (also known as mild traumatic brain in

Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial-stage ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is now available in the United States for the treatment of presbyopia in adults. Presbyopia, the gradual loss of close-up vision that typically begins around age 45, affects about 128 million p

CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small dose third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), today announced results from two moderated oral poster presentations at the March 28-30, 2026 American College of Cardiology meeting in New Orleans. “The 72-week open-label study, which over 90% of participants completed, provides further information on lerodalcibep’s longer term

Randomized IDE study met all primary and secondary safety and efficacy endpoints and demonstrated superior debris capture and significantly higher technical success versus the leading embolic protection control device in TAVR SANTA CRUZ, Calif., March 30, 2026 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company developing embolic protection solutions for structural heart procedures, today announced positive results from its pivotal PROTECT H2H global clinical trial evalua

PHOENIXVILLE, Pa., March 30, 2026 /PRNewswire/ -- PleoPharma, Inc., a privately held company focused on finding treatments for cannabis related health issues, announced today that management will present at the Centri Capital Conference in New York City on April 14, 2026 at 8:30 a.m. Eastern Time (ET). About PleoPharma, Inc. PleoPharma, Inc. is a clinical stage development company in the neuropsych and addiction space focused on finding solutions for people suffering from cannabis addiction and